<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1650">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05139680</url>
  </required_header>
  <id_info>
    <org_study_id>B3461099</org_study_id>
    <nct_id>NCT05139680</nct_id>
  </id_info>
  <brief_title>Real-World Effectiveness of Tafamidis on Neurologic Disease Progression in Patients With Mixed Phenotype Hereditary Transthyretin Amyloidosis Cardiomyopathy</brief_title>
  <official_title>Real-World Effectiveness of Tafamidis 80 mg or 61 mg on Neurologic Disease Progression in Patients With Mixed-Phenotype Hereditary Transthyretin Amyloid Cardiomyopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <brief_summary>
    <textblock>
      This will be an observational, retrospective cohort study using structured secondary&#xD;
      anonymized data. Patients with mixed-phenotype ATTRv-CM receiving high dose tafamidis for at&#xD;
      least 12 months will be identified. Relevant data will be extracted through at least 12&#xD;
      months following the initiation of tafamidis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Transthyretin amyloidosis (ATTR amyloidosis) is a rare, life-threatening disease caused by&#xD;
      the deposition of transthyretin-derived amyloid fibrils in the peripheral nerves, heart, and&#xD;
      other organs. ATTR amyloidosis may arise from mutations in the transthyretin (TTR) gene&#xD;
      (ATTRv amyloidosis), or from the aggregation of wild-type TTR (ATTRwt amyloidosis). ATTRv&#xD;
      amyloidosis is now widely recognized as a spectrum of disease that can manifest as&#xD;
      polyneuropathy, cardiomyopathy, or a mixed phenotype. This non-interventional study will&#xD;
      examine the value of high dose tafamidis for delaying neurologic disease progression in&#xD;
      mixed-phenotype ATTRv-CM patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 22, 2021</start_date>
  <completion_date type="Anticipated">December 22, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of neurologic disease progression</measure>
    <time_frame>Baseline through at least 12 months of treatment</time_frame>
    <description>Describe and compare the rate of neurologic disease progression before and after initiation of tafamidis in patients with mixed-phenotype ATTRv-CM receiving tafamidis 80 mg or 61 mg daily in a real-world setting.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in modified Body Mass Index (BMI)</measure>
    <time_frame>Baseline (BL) through at least 12 months of treatment</time_frame>
    <description>Assess change from BL in mBMI in patients with mixed-phenotype ATTRv-CM receiving 80 mg or 61 mg tafamidis</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Hereditary Transthyretin Amyloidosis (ATTRv) Cardiomyopathy (CM), Mixed Phenotype</condition>
  <arm_group>
    <arm_group_label>Patients with mixed phenotype ATTRv-CM</arm_group_label>
    <description>Hereditary ATTR-CM patients presenting with mixed phenotype</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tafamidis</intervention_name>
    <description>80 or 61 milligrams (mg)</description>
    <arm_group_label>Patients with mixed phenotype ATTRv-CM</arm_group_label>
    <other_name>Vyndaqel</other_name>
    <other_name>Vyndamax</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study will include patients with mixed-phenotype ATTRv-CM who are treated in the&#xD;
        Amyloidosis Program at the Pennsylvania Presbyterian Medical Center of the University of&#xD;
        Pennsylvania. All patients meeting the study enrollment criteria will be included.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥18 years at diagnosis&#xD;
&#xD;
          2. Diagnosed with hereditary ATTR-CM, mixed phenotype&#xD;
&#xD;
          3. Treated with tafamidis (VYNDAQEL 80 mg [four 20-mg tafamidis meglumine capsules]&#xD;
             orally once daily or VYNDAMAX 61 mg [one 61-mg tafamidis capsule] orally once daily)&#xD;
             for ≥12 months&#xD;
&#xD;
          4. Have had ≥1 pre- and ≥2 post-treatment neurologic assessments&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of organ transplant&#xD;
&#xD;
          2. Wild-type TTR genotype&#xD;
&#xD;
          3. Individuals who are non-ambulatory&#xD;
&#xD;
          4. Prior treatment with any disease-modifying therapy (investigational or approved) alone&#xD;
             or in combination, except tafamidis, as either VYNDAQEL 80 mg (four 20-mg tafamidis&#xD;
             meglumine capsules) orally once daily or VYNDAMAX 61 mg (one 61-mg tafamidis capsule)&#xD;
             orally once daily&#xD;
&#xD;
          5. Peripheral neuropathy attributed to causes other than ATTR amyloidosis (e.g., diabetes&#xD;
             mellitus, B12 deficiency, HIV infection)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Amyloidosis Program at the Pennsylvania Presbyterian Medical Center of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Pfizer CT.gov Call Center</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 17, 2021</study_first_submitted>
  <study_first_submitted_qc>November 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 1, 2021</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>transthyretin</keyword>
  <keyword>amyloidosis</keyword>
  <keyword>cardiomyopathy</keyword>
  <keyword>tafamidis</keyword>
  <keyword>polyneuropathy</keyword>
  <keyword>progression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amyloid Neuropathies, Familial</mesh_term>
    <mesh_term>Nervous System Diseases</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Amyloidosis</mesh_term>
    <mesh_term>Disease Progression</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

